上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
Tesirine (Synonyms: SG3249) 纯度: 97.96%
Tesirine (SG3249) 是一种抗体偶联药物 (ADC) 的吡咯苯并二氮卓 (PBD) 二聚体。Tesirine 结合了抗肿瘤活性和理想的物理化学性质,如良好的疏水性和改进的共轭特性。SG3199 (HY-101161) 是 ADC 有效载荷 Tesirine 的释放弹头成分。SG3199 在一组癌细胞系中保持皮摩尔活性。PBD 二聚体是一种高效的 DNA 小沟交联剂,具有很强的细胞毒性。
Tesirine Chemical Structure
CAS No. : 1595275-62-9
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
1 mg | ¥19200 | In-stock | |
5 mg | ¥64000 | In-stock | |
10 mg | ¥105000 | In-stock | |
50 mg | 询价 | ||
100 mg | 询价 |
* Please select Quantity before adding items.
生物活性 |
Tesirine (SG3249) is an antibody-drug conjugate (ADC) pyrrolobenzodiazepine (PBD) dimer payload. Tesirine combines potent antitumor activity with desirable physicochemical properties such as favorable hydrophobicity and improved conjugation characteristics. SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 retains picomolar activity in a panel of cancer cell lines. PBD dimers are highly efficient DNA minor groove cross-linking agents with potent cytotoxicity[1][2]. |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
IC50 & Target |
|
||||||||||||||||
体外研究 (In Vitro) |
SG3199 (HY-101161) is the released warhead component of the ADC payload Tesirine. SG3199 inhibits K562, NCIN87, BT474, and SKBR3 cancer cells with IC50s of 150 pM, 20 pM, 1 nM and 320 pM[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
Clinical Trial |
|
||||||||||||||||
分子量 |
1496.65 |
||||||||||||||||
Formula |
C75H101N9O23 |
||||||||||||||||
CAS 号 |
1595275-62-9 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
-20°C, protect from light, stored under nitrogen *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen) |
||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 200 mg/mL (133.63 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
|
||||||||||||||||
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务